Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)

Eton Pharmaceuticals' Cash from Financing Activities history spans 7 years, with the latest figure at $394000.0 for Q1 2025.

  • For Q1 2025, Cash from Financing Activities rose 204.23% year-over-year to $394000.0; the TTM value through Sep 2025 reached $34.0 million, up 2768.19%, while the annual FY2024 figure was $32.6 million, 3505.75% up from the prior year.
  • Cash from Financing Activities for Q1 2025 was $394000.0 at Eton Pharmaceuticals, down from $33.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $33.6 million in Q4 2024 and bottomed at -$385000.0 in Q1 2022.
  • The 5-year median for Cash from Financing Activities is -$49000.0 (2023), against an average of $1.9 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 1154.29% in 2023 before it surged 11519.05% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $68000.0 in 2021, then skyrocketed by 45.59% to $99000.0 in 2022, then tumbled by 396.97% to -$294000.0 in 2023, then soared by 11519.05% to $33.6 million in 2024, then plummeted by 98.83% to $394000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Cash from Financing Activities are $394000.0 (Q1 2025), $33.6 million (Q4 2024), and -$385000.0 (Q3 2024).